Facebook
Instagram
Linkedin
Youtube
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Search
BioStock
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Home
Search
aptahem
-
search results
If you're not happy with the results, please do another search
Aptahem teams up with Hongene
14 April, 2025
Aptahem reports growing buzz around Apta-1
1 April, 2025
Aptahem comments on the publication in Cells
29 February, 2024
Watch the interviews from BioStock Investor Meeting!
26 September, 2023
Watch the presentations from BioStock Investor Meeting!
22 September, 2023
Aptahem’s CEO comments on Q2 and looks ahead
5 September, 2023
Aptahem comments on the paused phase I study
24 July, 2023
Aptahem takes the next step in the treatment of sepsis
27 June, 2023
Aptahem gives update on operations and rights issue
21 June, 2023
The BioStock Life Science Spring Summit 2023 goes live today
30 May, 2023
Aptahem on the need for more effective sepsis treatments
28 April, 2023
BioStock Life Science Summit May 2023
5 April, 2023
Aptahem’s CEO sees continued interest in Apta-1
31 March, 2023
BioStock Investor Meeting September 2023
22 March, 2023
Further steps in Aptahem’s phase I study
28 February, 2023
Aptahem’s CEO on upcoming milestones
24 November, 2022
Aptahem’s CEO comments on the rights issue
10 November, 2022
Aptahem provides an operational update
31 October, 2022
Aptahem on the application to initiate clinical studies
26 September, 2022
Aptahem on the importance of raising sepsis awareness
16 September, 2022
Aptahem on schedule for clinical studies
31 August, 2022
Aptahem increasingly close to clinical studies
15 August, 2022
Lipum has wind in its sails for phase I
8 August, 2022
Aptahem’s new CMO on her role and vision
17 June, 2022
Aptahem signs agreement with CRO for phase I studies
23 May, 2022
BioStock Investor Meeting 16 March
16 March, 2022
Aptahem on the latest news
9 March, 2022
Aptahem’s Q4 lays groundwork for clinical studies
15 February, 2022
Aptahem recruits to key positions before clinical studies
4 February, 2022
BioStock Investor Meeting, March 16
27 January, 2022
Aptahem’s CEO on clinical studies in 2022
21 December, 2021
Aptahem’s new research findings explained
2 December, 2021
Eight CEOs on their expectations at BIO-Europe
25 October, 2021
Join us for the BioStock Life Science Summit on October 20...
20 October, 2021
BioStock Live: World Sepsis Day Seminar with Aptahem
13 September, 2021
Aptahem’s CEO looks forward to an exciting second half of the...
12 July, 2021
Aptahem on the potential for collaboration with the US military
5 July, 2021
Sepsis – common complication in connection with Covid-19 infection
5 July, 2021
Aptahem on the company’s new research findings
5 July, 2021
Aptahem’s new CRD brings clinical experience to Phase I
5 July, 2021
Aptahem on the comparative study between Apta-1 and dexamethasone
4 July, 2021
Positive results from Aptahem’s collaboration with Örebro University
4 July, 2021
Aptahem comments on the new Covid-19 project
4 July, 2021
CombiGene’s new Chairman on visions for the future
4 July, 2021
Aptahem’s founder is back – now as Chairman of the Board
3 July, 2021
Aptahem approaching milestone via oversubscribed rights issue
3 July, 2021
Aptahem looks ahead with optimism
2 July, 2021
Aptahem’s wish list for next year’s Christmas
2 July, 2021
BioStock Studio: Aptahem´s CSO on the sepsis candidate Apta-1
2 July, 2021
Aptahem has identified a mechanism of action for Apta-1
1 July, 2021
Aptahem’s Chairman of the Board on the latest news
1 July, 2021
Aptahem’s chief operating officer on the plans for 2021
26 May, 2021
Aptahem’s Scientific Advisors on Sepsis Candidate Apta-1
24 March, 2021
Aptahem’s CEO on signing of non binding Term Sheet
10 March, 2021
Strong opening to BioStock Life Science Summit 2019 – see videos...
31 October, 2019